MEACOR is developing Cryocinch, a proprietary transcatheter cryoadhesion technology that implants interconnected anchors along the valve annulus to treat mitral and tricuspid regurgitation. Cryocinch leverages on-demand cryoadhesion to compensate for cardiac motion and enable precise, reproducible implantation. The company positions the approach as a minimally invasive alternative to open-heart surgery and edge-to-edge repair, with potential benefits including shorter recovery, reduced complication risk, and lower overall costs. MEACOR plans to grow its team and rapidly achieve critical R&D and clinical milestones while maintaining lean and efficient R&D and clinical operations. It has recruited senior clinical advisors Dr. Azeem Latib and Dr. Susheel Kodali and named Rick Geoffrion as a senior business advisor to support development and commercialization. MEACOR recently closed a $15 million Series A to support these efforts and is based in Boston.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

May 2024